CP3 Study First to Quantify Gene Therapy Trial Funding

A recent paper in JAMA is the first to quantify the funding sources of gene therapy trials in the United States.  Lead author and CP3 Director, Dr. Walid Gellad, spoke with BioPharma Dive about the paper. "This is a sign that the model of drug development that was prominent in the past — academia does basic science and finds some targets and then pharma develops the actual drug product — is pretty different with gene therapy," Gellad noted. The paper's authors determined that academia - hospitals and universities - funded the majority of the gene therapy trials in the study cohort.